Working... Menu

A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02452372
Recruitment Status : Completed
First Posted : May 22, 2015
Last Update Posted : June 14, 2018
Information provided by (Responsible Party):
Alnylam Pharmaceuticals

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : September 6, 2017
  Actual Study Completion Date : September 6, 2017